Want to join the conversation?
Globally, $AMGN's product sales grew 6% in 3Q15 and US business grew 20%. International business grew 3% YoverY, excluding the negative impact of FX. Repatha is expected to be approved in Japan in 1H16. Kyprolis, which grew 46% in 3Q15, is expected to be approved in Europe, Canada and parts of South America and Asia by year-end.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.